A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants
Phase of Trial: Phase II
Latest Information Update: 06 Dec 2019
Price : $35 *
At a glance
- Drugs GSK 3359609 (Primary) ; Docetaxel
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development
- 26 Oct 2019 Planned End Date changed from 29 Mar 2022 to 9 Dec 2021.
- 26 Oct 2019 Planned primary completion date changed from 16 Jun 2020 to 28 Feb 2020.
- 23 Sep 2019 Planned End Date changed from 30 Dec 2022 to 29 Mar 2022.